Company intelligence / Profile preview

HLB Genex

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

HLB Genex is a South Korean biotechnology company and a subsidiary of the HLB Group, focused on the development of innovative therapies for cancer and neurodegenerative diseases. The company leverages its relationship with the broader HLB ecosystem to advance clinical-stage assets, including collaborations on VEGFR inhibitors and immunotherapy combinations. HLB Genex is particularly active in exploring gene and cell therapy applications to address high unmet medical needs in oncology. Its business model involves a mix of internal R&D and strategic partnerships to accelerate the commercialization of its pipeline candidates.

Therapeutic areas: NeurologyOncology
Modalities: Small moleculeGene therapyCell therapy
Industry: Biotech

Partnerships

HLB Life ScienceElevar Therapeutics

Beyond the preview

Go deeper on HLB Genex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLB Genex.

Explore the full profile